000 01263 a2200397 4500
005 20250517163356.0
264 0 _c20181211
008 201812s 0 0 eng d
022 _a2040-3372
024 7 _a10.1039/c7nr03042h
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aPapi, M
245 0 0 _aClinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.
_h[electronic resource]
260 _bNanoscale
_cJul 2017
300 _a10327-10334 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aCell Line, Tumor
650 0 4 _aDrug Delivery Systems
650 0 4 _aHumans
650 0 4 _aLiposomes
650 0 4 _aNanoparticles
_xchemistry
650 0 4 _aPolyethylene Glycols
_xchemistry
650 0 4 _aProtein Corona
700 1 _aCaputo, D
700 1 _aPalmieri, V
700 1 _aCoppola, R
700 1 _aPalchetti, S
700 1 _aBugli, F
700 1 _aMartini, C
700 1 _aDigiacomo, L
700 1 _aPozzi, D
700 1 _aCaracciolo, G
773 0 _tNanoscale
_gvol. 9
_gno. 29
_gp. 10327-10334
856 4 0 _uhttps://doi.org/10.1039/c7nr03042h
_zAvailable from publisher's website
999 _c27362790
_d27362790